Lv3
220 积分 2021-05-21 加入
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
20天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
21天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
21天前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
1个月前
已完结
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial
4个月前
已完结
Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation
5个月前
已完结
Axitinib or bevacizumab plus folfox or modified folfox-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study
5个月前
已完结
皖公网安备34019202002308
